MAJOR SHAREHOLDERS 18 18.1.2 HISTORY OF ALLOCATION OF SHARE CAPITAL Shareholders As of December 31, 2015 As of December 31, 2016 As of December 31, 2017 Number % of share Number % of share Number % of share of shares/ capital/ of shares/ capital/ of shares/ capital/ voting rights voting rights voting rights voting rights voting rights voting rights pre-reverse post-reverse post-reverse stock split stock split stock split Founders 1,710,684 12.57% 1,710,684 8.81% 2,095,086 8.65% Novartis Pharma AG 2,771,774 20.37% 3,521,774 18.14% 3,521,774 14.53% Abingworth Bioventures VI LP 2,322,056 17.06% 2,873,306 14.80% 3,139,973 12.96% Versant 2,322,048 17.06% 2,947,048 15.18% 3,280,381 13.54% Vitavest S.à.r.l 1,018,440 7.48% 1,206,373 6.22% 1,339,706 5.53% Bpifrance Investissement 663,166 4.87% 975,666 5.03% 975,666 4.03% Fidelity 1,284,680 9.44% 1,860,895 9.59% 1,628,865 (1) 6.72% Bpifrance Participations — 0% 1,500,000 7.73% 2,000,000 8.25% Other investors 1,516,274 11.14% 2,813,955 14.50% 6,252,772 25.80% Total 13,609,122 100% 19,409,701 100% 24,234,223 100,00% (1) As per public filing dated January 31, 2018. During the last three years, the following events have changed • In 2017: the number and classes of the issued and our outstanding shares: – On June 27, 2017, we issued 3,750,000 ordinary shares in a • In 2015: private placement on Euronext Paris for which we received – On July 7, 2015, we canceled all share warrants attached to net proceeds of €20,724 K. the Series A preferred shares. – On July 7, 2015, we issued 11,562,178 (corresponding 18.2 to 4,624,871 post reverse stock split) Series B preferred shares in a private placement to 19 investors pursuant SHAREHOLDERS’ VOTING RIGHTS to an investment agreement dated June 30, 2015 which Each of our share, either ordinary or preferred, entitles the holder terminated upon completion of the listing of our shares on to one vote. Euronext Paris. Our bylaws, by express derogation to article L.225-123 • In 2016: paragraph 3 of the French Commercial Code, do not grant double – On July 13, 2016, we completed our Initial Public Offering voting rights to our shares. (IPO) on Euronext Paris, raising €40.0 mil lion, and issued 5,000,000 ordinary shares. – On August 10, 2016, we partly exercised the overallotment 18.3 option as part of our IPO on Euronext Paris, raising an CONTROL STRUCTURE additional €5.2 million, and issued 655,859 ordinary shares. As of the date of this Registration Document, no shareholder has – These figures give effect to the 5-for-2 reverse split of our exclusive control over the Company. outstanding shares approved by the general shareholders’ meeting on August 17, 2015, which became effective on September 3, 2015, 15 days after publication of the notice of the split in the French Bulletin des Annonces Légales Obligatoires, or BALO, pursuant to French law. 178– GENSIGHT BIOLOGICS – 2017 Registration Document